Related Experiment Videos
[Application of chronotherapy to cardiovascular diseases]
Insights
Chronotherapy optimizes cardiovascular disease treatment by timing medications to the body's natural rhythms. Strategic drug administration, particularly slow-release formulations, improves blood pressure control and reduces adverse event incidence.
Area of Science:
- Cardiology
- Pharmacology
- Chronobiology
Context:
- Cardiovascular diseases like hypertension and ischemic stroke exhibit circadian patterns, with increased risk in the morning.
- Chronotherapy leverages these biological rhythms to enhance treatment efficacy.
- Slow-release drug formulations are key for sustained 24-hour therapeutic effects with once-daily dosing.
Purpose:
- To explore the principles of chronotherapy in managing cardiovascular diseases.
- To detail optimal timing strategies for antihypertensive and anti-ischemic medications based on patient profiles and drug types.
- To highlight the role of drug release kinetics in chronotherapeutic applications.
Summary:
- For primary hypertension, morning administration of beta-blockers and calcium antagonists is effective, while ACE-inhibitors are better in the evening.
- Evening dosing of calcium antagonists benefits secondary hypertension.
- Severe hypertension requires polytherapy with at least one evening dose to manage nocturnal blood pressure.
- In ischemic heart disease, morning administration of beta-blockers and calcium antagonists is effective; nitrates require timing based on pain onset.
- Aspirin (ASA) may reduce morning heart attacks, and tissue-type plasminogen activator shows circadian variation in efficacy.
Impact:
- Optimized medication timing can improve blood pressure control and reduce the incidence of cardiovascular events.
- Personalized chronotherapy strategies can enhance treatment outcomes for hypertension and ischemic heart disease.
- Understanding circadian variations in drug activity and disease presentation allows for more effective therapeutic interventions.
Abstract:
Among cardiovascular diseases, hypertension, angina pectoris, acute myocardial infarction and ischemic stroke present a circadian pattern with a greater incidence of unfavourable events between awakening and noon. Chronotherapy aims to use drugs that release their active principles at different times during the day, according to biological needs. In chronotherapy of cardiovascular diseases, a particular attention has been paid to slow-release drugs that assure a 24 hours therapeutic effect with once a day administration. In primary hypertension well controlled by monotherapy (dipper hypertensives), the morning administration of long-acting beta-blockers and calcium antagonists has shown to control blood pressure over 24 hours, whereas ACE-inhibitors have proved more effective when administered at evening. In secondary hypertension (non dipper hypertensives) the administration of calcium antagonists is more effective at evening. Patients with severe hypertension need polytherapy. In that case, at least one of the antihypertensive drugs should be given at evening to lower night blood pressure values, which are particularly elevated also during sleep, and so to prevent an excessive blood pressure rise on awakening. In chronic monotherapy of ischemic heart disease, long-acting beta-blockers and calcium antagonists have shown to be equally effective when they are administered at morning, whereas slow-release nitrates, which need a nitrate-free interval, are to be administered either at morning or at evening, according to the expected time of onset of anginal pain. ASA seems to reduce the morning incidence of acute myocardial infarction, while tissue-type plasminogen activator presents a circadian variation of its thrombolytic activity with a higher efficacy between noon and midnight.